Factors Associated with Worse Lung Function in Cystic Fibrosis Patients with Persistent Staphylococcus Aureus

Background: Staphylococcus aureus is an important pathogen in cystic fibrosis (CF). However, it is not clear which factors are associated with worse lung function in patients with persistent S. aureus airway cultures. Our main hypothesis was that patients with high S. aureus density in their respiratory specimens would more likely experience worsening of their lung disease than patients with low bacterial loads.

Methods: Therefore, we conducted an observational prospective longitudinal multi-center study and assessed the association between lung function and S. aureus bacterial density in respiratory samples, co-infection with other CF-pathogens, nasal S. aureus carriage, clinical status, antibiotic therapy, IL-6- and IgG-levels against S. aureus virulence factors.

Results: 195 patients from 17 centers were followed; each patient had an average of 7 visits. Data were analyzed using descriptive statistics and generalized linear mixed models. Our main hypothesis was only supported for patients providing throat specimens indicating that patients with higher density experienced a steeper lung function decline (p<0.001). Patients with exacerbations (n = 60), S. aureus small-colony variants (SCVs, n = 84) and co-infection with Stenotrophomonas maltophilia (n = 44) had worse lung function (p = 0.0068; p = 0.0011; p = 0.0103). Patients with SCVs were older (p = 0.0066) and more often treated with trimethoprim/sulfamethoxazole (p = 0.0078). IL-6 levels positively correlated with decreased lung function (p<0.001), S. aureus density in sputa (p = 0.0016), SCVs (p = 0.0209), exacerbations (p = 0.0041) and co-infections with S. maltophilia (p = 0.0195) or A. fumigatus (p = 0.0496).

Conclusions: In CF-patients with chronic S. aureus cultures, independent risk factors for worse lung function are high bacterial density in throat cultures, exacerbations, elevated IL-6 levels, presence of S. aureus SCVs and co-infection with S. maltophilia.

Trial Registration: ClinicalTrials.gov NCT00669760.

Citing Articles

Epidemiology and Antimicrobial Resistance of Stenotrophomonas maltophilia in China, 2014-2021.

Wang H, Li S, Ji H, Hu Y, Zhou S, Chen X Infect Dis Ther. 2024; 14(1):261-274.

PMID: 39731666 PMC: 11782787. DOI: 10.1007/s40121-024-01099-7.

Chronic Coinfection with Pseudomonas aeruginosa and Normal Colony Staphylococcus aureus Causes Lung Structural Damage in the Cystic Fibrosis Rat.

Bollar G, Keith J, Stanford D, Oden A, Raju S, Poore T Am J Pathol. 2024; 195(2):174-187.

PMID: 39476957 PMC: 11773620. DOI: 10.1016/j.ajpath.2024.09.008.

Thymidine-dependent Staphylococcus aureus and lung function in patients with cystic fibrosis: a 10-year retrospective case-control study.

Tomaz A, Souza D, Cogo L, Palmeiro J, Nogueira K, Petterle R J Bras Pneumol. 2024; 50(4):e20240026.

PMID: 39194074 PMC: 11449591. DOI: 10.36416/1806-3756/e20240026.

Practical Guidance for Clinical Microbiology Laboratories: Updated guidance for processing respiratory tract samples from people with cystic fibrosis.

Saiman L, Waters V, LiPuma J, Hoffman L, Alby K, Zhang S Clin Microbiol Rev. 2024; 37(3):e0021521.

PMID: 39158301 PMC: 11391703. DOI: 10.1128/cmr.00215-21.

Nuclease activity and protein A release of clinical isolates determine the virulence in a murine model of acute lung infection.

Ludwig N, Thorner-van Almsick J, Mersmann S, Bardel B, Niemann S, Chasan A Front Immunol. 2023; 14:1259004.

PMID: 37849760 PMC: 10577289. DOI: 10.3389/fimmu.2023.1259004.

References

Ridder-Schaphorn S, Ratjen F, Dubbers A, Haberle J, Falk S, Kuster P . Nasal Staphylococcus aureus carriage is not a risk factor for lower-airway infection in young cystic fibrosis patients. J Clin Microbiol. 2007; 45(9):2979-84. PMC: 2045257. DOI: 10.1128/JCM.00855-07. View

Sagel S, Gibson R, Emerson J, McNamara S, Burns J, Wagener J . Impact of Pseudomonas and Staphylococcus infection on inflammation and clinical status in young children with cystic fibrosis. J Pediatr. 2008; 154(2):183-8. PMC: 2654617. DOI: 10.1016/j.jpeds.2008.08.001. View

Stone A, Saiman L . Update on the epidemiology and management of Staphylococcus aureus, including methicillin-resistant Staphylococcus aureus, in patients with cystic fibrosis. Curr Opin Pulm Med. 2007; 13(6):515-21. DOI: 10.1097/MCP.0b013e3282efbbac. View

Ahlgren H, Benedetti A, Landry J, Bernier J, Matouk E, Radzioch D . Clinical outcomes associated with Staphylococcus aureus and Pseudomonas aeruginosa airway infections in adult cystic fibrosis patients. BMC Pulm Med. 2015; 15:67. PMC: 4475617. DOI: 10.1186/s12890-015-0062-7. View

Cogen J, Emerson J, Sanders D, Ren C, Schechter M, Gibson R . Risk factors for lung function decline in a large cohort of young cystic fibrosis patients. Pediatr Pulmonol. 2015; 50(8):763-70. PMC: 5462119. DOI: 10.1002/ppul.23217. View

Goerke C, Kraning K, Stern M, DORING G, Botzenhart K, Wolz C . Molecular epidemiology of community-acquired Staphylococcus aureus in families with and without cystic fibrosis patients. J Infect Dis. 2000; 181(3):984-9. DOI: 10.1086/315331. View

Li Z, Kosorok M, Farrell P, Laxova A, West S, Green C . Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis. JAMA. 2005; 293(5):581-8. DOI: 10.1001/jama.293.5.581. View

Goss C, Mayer-Hamblett N, Aitken M, Rubenfeld G, Ramsey B . Association between Stenotrophomonas maltophilia and lung function in cystic fibrosis. Thorax. 2004; 59(11):955-9. PMC: 1746887. DOI: 10.1136/thx.2003.017707. View

Wertheim H, Melles D, Vos M, van Leeuwen W, van Belkum A, Verbrugh H . The role of nasal carriage in Staphylococcus aureus infections. Lancet Infect Dis. 2005; 5(12):751-62. DOI: 10.1016/S1473-3099(05)70295-4. View

10.

Herwaldt L, Cullen J, French P, Hu J, Pfaller M, Wenzel R . Preoperative risk factors for nasal carriage of Staphylococcus aureus. Infect Control Hosp Epidemiol. 2004; 25(6):481-4. DOI: 10.1086/502426. View

11.

Waters V, Yau Y, Prasad S, Lu A, Atenafu E, Crandall I . Stenotrophomonas maltophilia in cystic fibrosis: serologic response and effect on lung disease. Am J Respir Crit Care Med. 2010; 183(5):635-40. DOI: 10.1164/rccm.201009-1392OC. View

12.

Hafner L, Peters G, Kahl B . Assessment of microbiological diagnostic procedures for respiratory specimens from cystic fibrosis patients in German laboratories by use of a questionnaire. J Clin Microbiol. 2014; 52(3):977-9. PMC: 3957798. DOI: 10.1128/JCM.02866-13. View

13.

den Reijer P, Lemmens-den Toom N, Kant S, Snijders S, Boelens H, Tavakol M . Characterization of the humoral immune response during Staphylococcus aureus bacteremia and global gene expression by Staphylococcus aureus in human blood. PLoS One. 2013; 8(1):e53391. PMC: 3538780. DOI: 10.1371/journal.pone.0053391. View

14.

Mensa J, Trilla A . Should patients with acute exacerbation of chronic bronchitis be treated with antibiotics? Advantages of the use of fluoroquinolones. Clin Microbiol Infect. 2006; 12 Suppl 3:42-54. PMC: 7128137. DOI: 10.1111/j.1469-0691.2006.01396.x. View

15.

Mardi D, Fwity B, Lobmann R, Ambrosch A . Mean cell volume of neutrophils and monocytes compared with C-reactive protein, interleukin-6 and white blood cell count for prediction of sepsis and nonsystemic bacterial infections. Int J Lab Hematol. 2009; 32(4):410-8. DOI: 10.1111/j.1751-553X.2009.01202.x. View

16.

Gaini S, Koldkjaer O, Pedersen C, Pedersen S . Procalcitonin, lipopolysaccharide-binding protein, interleukin-6 and C-reactive protein in community-acquired infections and sepsis: a prospective study. Crit Care. 2006; 10(2):R53. PMC: 1550885. DOI: 10.1186/cc4866. View

17.

Kerem E, Viviani L, Zolin A, Macneill S, Hatziagorou E, Ellemunter H . Factors associated with FEV1 decline in cystic fibrosis: analysis of the ECFS patient registry. Eur Respir J. 2013; 43(1):125-33. DOI: 10.1183/09031936.00166412. View

18.

Amin R, Dupuis A, Aaron S, Ratjen F . The effect of chronic infection with Aspergillus fumigatus on lung function and hospitalization in patients with cystic fibrosis. Chest. 2009; 137(1):171-6. DOI: 10.1378/chest.09-1103. View

19.

McKone E, Emerson S, Edwards K, Aitken M . Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study. Lancet. 2003; 361(9370):1671-6. DOI: 10.1016/S0140-6736(03)13368-5. View

20.

Liou T, Elkin E, Pasta D, Jacobs J, Konstan M, Morgan W . Year-to-year changes in lung function in individuals with cystic fibrosis. J Cyst Fibros. 2010; 9(4):250-6. PMC: 4102928. DOI: 10.1016/j.jcf.2010.04.002. View